You are here

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
City of Hope
Duarte, California, 91010 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non Small Cell Lung Cancer (NSCLC)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Advanced Non-Small Cell Lung Cancer (NSCLC).

- For Cohort I and Cohort II, advanced NSCLC patients must have received at least one
prior regimen of systemic therapy which includes at least one standard chemotherapy
for advanced NSCLC and who have failed (ie, progressed or intolerant due to toxicity
which precludes further treatment) standard therapy for advanced or metastatic
disease. To be considered intolerant to treatment, a patient must have received at
least two cycles to be considered previously treated.

- For Cohort III, advanced NSCLC patients must not have received prior systemic
treatment for their advanced disease and require a known EGFR (HER-1) mutation, HER-2
mutation or HER-2 amplification. Cohort III patients could have received prior
adjuvant chemotherapy for Stage I-III disease or combined modality
chemotherapy-radiation for Stage IIIA disease is allowed if treatment completed>12
months prior to enrollment.

- All cohorts, patients must have evidence of disease; however, measurable disease is
not required to enroll.

- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2

- Estimated creatinine clearance ≥15 mL/min.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior treatment with an EGFR-targeted or HER-targeted agent (all cohorts).

- Chemotherapy, radiotherapy, biological or investigational agents within 2 weeks of
baseline disease assessments (all cohorts).

- Patients with known diffuse interstitial lung disease (all cohorts).

- Investigational therapy as only treatment for advanced NSCLC without administration of
an approved chemotherapy for advanced NSCLC (for Cohort I and Cohort II)

NCT01465802
Pfizer
Completed
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now